$HD lifted its earnings per share growth guidance for FY16, principally because of better expense control and more than expected operating leverage. Diluted EPS is now expected to grow by approx. 15.6% to $6.31. Earlier, the company had estimated diluted EPS to be $6.27 for FY16.
$NBR's subsidiary Nabors Industries Inc. (NII) commenced offering of senior unsecured notes due 2023. The notes will be fully and unconditionally guaranteed by $NBR. The proceeds are intended to be used to prepay $162.5MM portion due in 2018 under NII's $325MM unsecured term loan and outstanding under NII's unsecured revolving credit facility.
$ABBV announced efficacy and safety findings from two separate studies evaluating ibrutinib as a combination therapy in two of the most common types of non-Hodgkin's lymphoma: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Preliminary efficacy results demonstrated highest response rate was observed in patients.
$ALXN said new data from ALXN1210 dose-escalation study were presented at ASH. This showed rapid and sustained reductions in lactate dehydrogenase (LDH), a direct marker of hemolysis (the destruction of red blood cells), in patients with paroxysmal nocturnal hemoglobinuria (PNH).
$THC and $UNH renewed national relationship for four years. This ensures all $UNH commercial and Medicare Advantage plan participants have continued in-network access to $THC's hospitals, outpatient centers and employed physicians across the country.